RYTM
Rhythm Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
92.57
close · 2026-10-30
value
76
cheaper than peers76
quality
36
stronger fundamentals36
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -3.5% | 80 |
| cash flow yield, 1 year ago | -1.8% | 78 |
| cash flow yield, 2 years ago | -2.1% | 76 |
| earnings yield, 3 years ago | -3.7% | 75 |
| cash flow yield, latest year | -1.8% | 74 |
| earnings yield, 1 year ago | -4.7% | 72 |
| cash flow yield, 3 years ago | -2.8% | 72 |
| earnings yield, latest year | -3.4% | 69 |
| price to sales | 26.57× | 32 |
| price to book | 61.88× | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 46.9% | 64 |
| operating margin | -68.1% | 59 |
| debt to equity | 50.5% | 31 |
| return on equity | -117.0% | 21 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | -$130.6M |
| employees | 414 |
| first trade | 2017-10-09 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.11 | -4.34 | -3.20 | -3.47 |
| free cash flow | -$116.6M | -$113.9M | -$136.2M | -$177.7M |
| net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M |
| revenue | $189.8M | $130.1M | $77.4M | $23.6M |
| unusual items | not reported | $8.9M | not reported | not reported |